Cronos Group Inc. Common Share (CRON) exhibits 42.8% gross margins and -4.5% return on invested capital within Health Care (Medicinal Chemicals and Botanical Products), balanced against a 24.0x enterprise multiple and 4.8% implied options volatility.
Sustained 42.8% gross profitability converts into -11.9% operating margin and -4.5% ROIC, outpacing sector cost of capital.
ROIC: -4.5% // GM: 42.8%YoY revenue trajectory of +24.6% paired with 0.01% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +24.6% // FCF YLD: 0.01%Altman Z-Score of 15.20 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 15.20 // F-SCORE: 6/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $3.36 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Medicinal Chemicals and Botanical Products require continuous execution to defend -2.0% net margins.
NET MARGIN: -2.0% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for CRON & activate live FRED threshold breach alerts.